# 9Bio Therapeutics

> Engineering Biological Possibilities


## Posts

- [9Bio Therapeutics selected by the Merck Digital Sciences Studio and CQDM for strategic investment and acceleration program](https://9biotx.com/news/9bio-therapeutics-selected-by-merck-global-health-innovation-fund-and-cqdm-for-strategic-investment-and-acceleration-program/): 9Bio Therapeutics is proud to announce a strategic investment from the Merck Digital Sciences Studio (MDSS) and CQDM. The funding will accelerate the development of 9Bio’s computationally guided discovery platform and pipeline of tumor-selective therapies.
- [$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation](https://9biotx.com/news/1-8m-quebec-backed-collaboration-between-9bio-and-vega-advances-precision-oncology-innovation/): 9Bio Therapeutics and Vega BioImaging, a startup developing innovative companion diagnostics for cancer treatments, are pleased to announce a collaborative $1.8 million initiative in targeted oncology therapies. The project has received significant support from the Government of Quebec, in the form of a $0.9 million grant through CQDM’s Partenar-IA program, in partnership with IVADO.
- [9Bio Therapeutics and TransBIOTech awarded $450,000 Applied Research and Development (ARD) grant to accelerate oncology innovation](https://9biotx.com/news/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation/): In partnership with TransBIOTech (Levis, QC), 9Bio Therapeutics has been awarded a $450,000 Applied Research and Development (ARD) grant via the College and Community Innovation (CCI) program, administered through the Natural Sciences and Engineering Research Council of Canada (NSERC) in collaboration with the Social Sciences and Humanities Research Council (SSHRC) and Canadian Institutes of Health Research (CIHR).
- [9Bio Therapeutics secures strategic funding to advance its oncology pipeline](https://9biotx.com/news/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline/): 9Bio Therapeutics is pleased to announce its participation in a $2M project initiative alongside CQDM, IVADO, and two Quebec-based biotech companies. This funding will accelerate the preclinical development of highly targeted, safer cancer therapies, leveraging artificial intelligence (AI) and structural biology to redefine drug discovery.
- [9Bio Therapeutics honored with DEVTECH award by Québec International and Québec VITAE](https://9biotx.com/news/9bio-therapeutics-honored-with-devtech-award-by-quebec-international-and-quebec-vitae/): 9Bio Therapeutics is proud to announce its recognition at this year’s DEVTECH Life Sciences and Health Technologies Entrepreneurial Competition. This award, presented by Québec International and Québec VITAE, acknowledges the potential of 9Bio's team and platform technology to develop conditionally active therapies targeting the tumor microenvironment.
- [9Bio Therapeutics joins adMare BioInnovations' National Therapeutics Accelerator](https://9biotx.com/news/9bio-therapeutics-joins-admare-bioinnovations-national-therapeutics-accelerator/): 9Bio Therapeutics is proud to announce its acceptance into the adMare BioInnovations National Therapeutics (Tx) Accelerator. This strategic partnership aims to advance 9Bio's mission of developing targeted cancer therapies that prioritize patient safety and treatment efficacy.
- [9Bio is awarded a grant from the National Research Council Canada (NRC-IRAP)](https://9biotx.com/news/9bio-is-awarded-a-grant-from-the-national-research-council-canada-nrc-irap/): 9Bio Therapeutics is pleased to announce that it will receive $75,000 in funding from the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) to support the development of its lead program – a precision antibody-drug conjugate (ADC).

## Pages

- [Pipeline](https://9biotx.com/pipeline/): Pipeline Conditionally active precision oncology therapeutics 9Bio is committed to advancing highly selective, tumor-targeted therapeutics to broaden the transformative impact of cutting-edge oncology treatments to more patients. Our mission is guided by two key objectives. First, we leverage our innovative platform to minimize off-tumor target engagement and develop antibody-drug conjugates (ADCs) for tumor antigens previously deemed undruggable due to partial peripheral expression. This approach addresses critical unmet needs in cancer indications where five-year survival rates remain unacceptably low. Second, by enhancing specificity, we aim to improve the bioavailability and tolerability of our therapeutics, making them more efficacious and accessible to […]
- [Privacy Policy](https://9biotx.com/privacy-policy/): Privacy Policy Protecting Your Personal Information 9Bio Therapeutics Inc. (“9Bio”, “we”, “us”, “our”) is committed to protecting the privacy of all users who access our website and services. This Privacy Policy outlines our practices regarding the collection, use, and disclosure of personal information. By accessing or using our website and services, you agree to the terms of this Privacy Policy. If you disagree with any part of the policy, then you may not access our services. Information We CollectWe collect personal information from individuals and companies who engage with our services. This information may include, but is not limited to, […]
- [Terms & Conditions](https://9biotx.com/terms-and-conditions/): Terms and Conditions Understanding Our Agreement and Obligations Welcome to the 9Bio Therapeutics Inc.  (“9Bio”, “we”, “us”, “our”) website (“Website”). By accessing and using this Website, you agree to comply with and be bound by the following terms and conditions (“Terms”). Acceptance of TermsBy accessing and using this Website, you accept and agree to be bound by the terms and provisions of these Terms. If you disagree with any part of these Terms, please do not use our Website. Changes to the Terms9Bio reserves the right to modify these Terms at any time. Any changes will be effective immediately upon […]
- [About Us](https://9biotx.com/about-us/): About 9Bio Therapeutics 9Bio stands at the confluence of biology, structural engineering, and artificial intelligence, pioneering breakthroughs in oncology therapies that will shape tomorrow’s cancer care. Our Story 9Bio Therapeutics began with a visionary notion: What if we could strategically re-engineer the core biological processes that shape us? And by doing so, could we push the very limits of what’s conceivable to improve cancer patients’ health? Our journey is anchored in proteins – the intricate molecular agents central to biology, shaping both our potential and limitations. These extraordinary molecules orchestrate life, and our mission is to tailor them for roles […]
- [Home](https://9biotx.com/): Our Platform Poor targeting of oncology therapeutics damages healthy organs and tissues, resulting in reduced quality of life for patients due to severe side effects, limited efficacy, early treatment discontinuation, and reduced survival. 9Bio’s computationally-guided structural biology platform enhances the clinical impact of targeted cancer therapies by integrating tumor biochemistry to design drugs that selectively target tumors based on the unique metabolomic and chemical signatures of the cancer microenvironment, while sparing healthy tissues. This technology generates safer and more efficacious therapeutics, paving the way for novel and highly targeted cancer treatments. Our pipeline of two discovery-stage therapies illustrates the broad […]
- [Contact](https://9biotx.com/contact/): Contact Us Whether you’re seeking innovative solutions, keen on joining our mission, or simply wish to share your insights, we’d love to hear from you.
- [9Bio News](https://9biotx.com/news/)


[comment]: # (Generated by Hostinger Tools Plugin)